|
Avaliação DCF da Akoya Biosciences, Inc. (Akya) |
Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
Design Profissional: Modelos Confiáveis E Padrão Da Indústria
Pré-Construídos Para Uso Rápido E Eficiente
Compatível com MAC/PC, totalmente desbloqueado
Não É Necessária Experiência; Fácil De Seguir
Akoya Biosciences, Inc. (AKYA) Bundle
Avalie as perspectivas financeiras da Akoya Biosciences, Inc. (Akya) com precisão especializada! Essa calculadora DCF (Akya) fornece dados financeiros pré-preenchidos e permite modificar facilmente o crescimento da receita, o WACC, as margens e outras suposições essenciais para se alinhar às suas projeções.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 42.4 | 54.9 | 74.9 | 96.6 | 81.7 | 97.9 | 117.3 | 140.5 | 168.4 | 201.8 |
| Revenue Growth, % | 0 | 29.39 | 36.31 | 29.09 | -15.48 | 19.83 | 19.83 | 19.83 | 19.83 | 19.83 |
| EBITDA | -10.1 | -35.2 | -58.8 | -45.6 | -37.1 | -50.7 | -60.8 | -72.8 | -87.3 | -104.6 |
| EBITDA, % | -23.86 | -64.04 | -78.57 | -47.22 | -45.47 | -51.83 | -51.83 | -51.83 | -51.83 | -51.83 |
| Depreciation | 3.8 | 4.8 | 7.1 | 8.9 | 7.7 | 9.0 | 10.8 | 12.9 | 15.4 | 18.5 |
| Depreciation, % | 8.99 | 8.73 | 9.55 | 9.2 | 9.37 | 9.17 | 9.17 | 9.17 | 9.17 | 9.17 |
| EBIT | -13.9 | -40.0 | -66.0 | -54.5 | -44.8 | -59.7 | -71.5 | -85.7 | -102.7 | -123.1 |
| EBIT, % | -32.85 | -72.76 | -88.12 | -56.42 | -54.84 | -61 | -61 | -61 | -61 | -61 |
| Total Cash | 17.0 | 113.1 | 81.2 | 83.1 | 35.0 | 72.2 | 86.5 | 103.7 | 124.3 | 148.9 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 6.5 | 9.4 | 9.7 | 17.0 | 13.8 | 15.6 | 18.7 | 22.5 | 26.9 | 32.2 |
| Account Receivables, % | 15.24 | 17.2 | 13 | 17.59 | 16.87 | 15.98 | 15.98 | 15.98 | 15.98 | 15.98 |
| Inventories | 4.3 | 9.0 | 14.5 | 17.9 | 24.3 | 18.4 | 22.1 | 26.4 | 31.7 | 38.0 |
| Inventories, % | 10.04 | 16.41 | 19.35 | 18.5 | 29.78 | 18.82 | 18.82 | 18.82 | 18.82 | 18.82 |
| Accounts Payable | 5.1 | 9.4 | 10.6 | 11.8 | 8.8 | 13.0 | 15.5 | 18.6 | 22.3 | 26.7 |
| Accounts Payable, % | 11.95 | 17.18 | 14.2 | 12.19 | 10.72 | 13.25 | 13.25 | 13.25 | 13.25 | 13.25 |
| Capital Expenditure | -3.3 | -5.1 | -7.4 | -3.7 | -2.5 | -6.6 | -7.9 | -9.5 | -11.3 | -13.6 |
| Capital Expenditure, % | -7.76 | -9.28 | -9.83 | -3.78 | -3.01 | -6.73 | -6.73 | -6.73 | -6.73 | -6.73 |
| Tax Rate, % | -0.2644 | -0.2644 | -0.2644 | -0.2644 | -0.2644 | -0.2644 | -0.2644 | -0.2644 | -0.2644 | -0.2644 |
| EBITAT | -14.0 | -39.8 | -66.1 | -54.6 | -44.9 | -59.7 | -71.5 | -85.7 | -102.6 | -123.0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -19.1 | -43.5 | -70.9 | -58.8 | -46.0 | -49.0 | -72.8 | -87.2 | -104.5 | -125.3 |
| WACC, % | 24.31 | 24.26 | 24.31 | 24.31 | 24.31 | 24.3 | 24.3 | 24.3 | 24.3 | 24.3 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -218.0 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -128 | |||||||||
| Terminal Value | -573 | |||||||||
| Present Terminal Value | -193 | |||||||||
| Enterprise Value | -411 | |||||||||
| Net Debt | -4 | |||||||||
| Equity Value | -407 | |||||||||
| Diluted Shares Outstanding, MM | 49 | |||||||||
| Equity Value Per Share | -8.24 |
What You Will Get
- Editable Forecast Inputs: Easily modify assumptions (growth %, margins, WACC) to explore various scenarios.
- Real-World Data: Akoya Biosciences, Inc.’s (AKYA) financial data pre-filled to accelerate your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically.
- Customizable and Professional: A refined Excel model that adjusts to your valuation requirements.
- Built for Analysts and Investors: Perfect for testing projections, validating strategies, and enhancing efficiency.
Key Features
- Comprehensive Data Access: Obtain precise pre-loaded historical performance metrics and future growth forecasts for Akoya Biosciences, Inc. (AKYA).
- Adjustable Assumptions: Modify highlighted fields such as discount rates, growth projections, and profit margins to tailor your analysis.
- Real-Time Calculations: Automatic recalculations for Discounted Cash Flow (DCF), Net Present Value (NPV), and cash flow assessments.
- Interactive Dashboard: Intuitive charts and summaries that facilitate the visualization of your valuation insights.
- Designed for All Users: A user-friendly layout suitable for investors, financial officers, and consultants, regardless of experience level.
How It Works
- 1. Access the Template: Download and open the Excel file containing Akoya Biosciences, Inc.'s (AKYA) preloaded data.
- 2. Adjust Key Inputs: Modify essential parameters such as revenue growth, WACC, and capital expenditures.
- 3. Analyze Results Immediately: The DCF model automatically computes intrinsic value and NPV based on your inputs.
- 4. Explore Different Scenarios: Evaluate various projections to understand a range of valuation possibilities.
- 5. Present with Assurance: Deliver expert valuation findings to bolster your decision-making process.
Why Choose Akoya Biosciences (AKYA)?
- Precision: Leverages cutting-edge technology for accurate biological data analysis.
- Customization: Users can easily adapt and modify parameters to suit their research needs.
- Efficiency: Streamlines complex workflows, saving valuable research time.
- High-Quality Standards: Engineered with the expertise of industry leaders to ensure reliability.
- Intuitive Interface: Designed for ease of use, catering to both seasoned scientists and newcomers.
Who Should Use This Product?
- Investors: Evaluate Akoya Biosciences’ valuation prior to making investment decisions.
- CFOs and Financial Analysts: Optimize valuation methodologies and assess financial forecasts.
- Biotech Entrepreneurs: Discover how leading biotech firms like Akoya are valued in the market.
- Consultants: Provide comprehensive valuation analyses and reports for clients in the biotech sector.
- Students and Educators: Utilize actual market data to learn and teach valuation strategies specific to biotechnology.
What the Template Contains
- Comprehensive DCF Model: Editable template featuring detailed valuation calculations tailored for Akoya Biosciences, Inc. (AKYA).
- Real-World Data: Akoya's historical and projected financials preloaded for thorough analysis.
- Customizable Parameters: Modify WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights into the company's performance.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage specific to Akoya Biosciences, Inc. (AKYA).
- Dashboard with Visual Outputs: Engaging charts and tables providing clear, actionable results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.